Puma touts its lat­est ad­vances in a bas­ket tri­al for Ner­l­ynx, as Eu­ro­peans ap­pear ready to re­ject the drug

While Eu­ro­pean reg­u­la­tors ap­pear ready to slap down Puma Biotech­nol­o­gy’s $PBYI first shot at an ap­proval for Ner­l­ynx (ner­a­tinib), the com­pa­ny is push­ing ahead with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER